General Information of Drug (ID: DMQDN46)

Drug Name
PLN-74809
Synonyms
Bexotegrast; PLN-74809; 2376257-44-0; QCV154PFT4; Pln 74809; Bexotegras; (2S)-4-(2-Methoxyethyl-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(quinazolin-4-ylamino)butanoic acid; (2S)-4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid; Bexotegras [INN]; Butanoic acid, 4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(4-quinazolinylamino)-, (2S)-; Butanoic acid, 4-[(2-methoxyethyl)[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(4-quinazolinylamino)-, (2S)-; bexotegrast [INN]; UNII-QCV154PFT4; CHEMBL5095257; SCHEMBL21329445; GTPL12108; US10793564, Compound 5; BDBM465216; GLXC-26826; (S)-4-((2-Methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(quinazolin-4-ylamino)butanoic acid; PLN 74809 [WHO-DD]; PLN74809; US10793564, Compound 55; BDBM50594476; AKOS040757614; MS-29155; HY-137561; CS-0140405; (S)-4-[(2-Methoxyethyl)[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(quinazolin-4-yl)amino]butanoic acid
Indication
Disease Entry ICD 11 Status REF
Idiopathic pulmonary fibrosis CB03.4 Phase 2 [1]
Primary sclerosing cholangitis DB96.2 Phase 2 [2]
Drug Type
Small molecule
Structure
3D MOL 2D MOL
Chemical Identifiers
Formula
C27H36N6O3
Canonical SMILES
COCCN(CCCCC1=NC2=C(CCCN2)C=C1)CCC(C(=O)O)NC3=NC=NC4=CC=CC=C43
InChI
InChI=1S/C27H36N6O3/c1-36-18-17-33(15-5-4-8-21-12-11-20-7-6-14-28-25(20)31-21)16-13-24(27(34)35)32-26-22-9-2-3-10-23(22)29-19-30-26/h2-3,9-12,19,24H,4-8,13-18H2,1H3,(H,28,31)(H,34,35)(H,29,30,32)/t24-/m0/s1
InChIKey
CWOFQJBATWQSHL-DEOSSOPVSA-N
Cross-matching ID
PubChem CID
135390719
TTD ID
D3MG8W
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Integrin alpha-5/beta-1 (ITGA5/B1) TTHWZMR ITAV_HUMAN-ITB1_HUMAN Inhibitor [3]
Integrin alpha-V/beta-6 (ITGAV/B6) TTIQSVM ITAV_HUMAN-ITB6_HUMAN Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05621252) A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Evaluation of PLN-74809 on Type 1 Collagen Deposition Using 68Ga-CBP8 PET/MRI Imaging in Participants With Idiopathic Pulmonary Fibrosis (IPF). U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT04480840) A Randomized, Double-blind, Dose-ranging, Placebo-controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Primary Sclerosing Cholangitis (PSC) and Suspected Liver Fibrosis (INTEGRIS-PSC). U.S.National Institutes of Health.
3 Dual inhibition of alpha(v)beta(6) and alpha(v)beta(1) reduces fibrogenesis in lung tissue explants from patients with IPF. Respir Res. 2021 Oct 19;22(1):265.